ONCODESIGN PRECISION MEDICINE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.3 EUR | 0.00% |
|
-7.80% | -28.18% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1M 1.09M | Sales 2025 * | 13.55M 14.73M | Capitalization | 21.65M 23.53M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -6.52M | Net income 2025 * | -7M -7.61M | EV / Sales 2024 * | 30.2 x |
| Net Debt 2024 * | 8.5M 9.24M | Net Debt 2025 * | 6.3M 6.85M | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
-3.42
x | P/E ratio 2025 * |
-3.25
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.38% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | -7.80% | ||
| Current month | -11.56% | ||
| 1 month | -17.46% | ||
| 3 months | -6.14% | ||
| 6 months | -42.48% | ||
| Current year | -28.18% |
1 week
1.26
1.42
1 month
1.261.54
Current year
1.262.06
1 year
1.052.39
3 years
0.622.50
5 years
0.622.50
10 years
0.622.50
| Managers | Title | Age | Since |
|---|---|---|---|
Philippe Genne
CEO | Chief Executive Officer | 62 | 22-08-30 |
Jan Hoflack
BRD | Director/Board Member | 63 | 22-09-13 |
Karine Lignel
BRD | Director/Board Member | 55 | 22-09-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kamel Besseghir
BRD | Director/Board Member | 75 | 22-09-13 |
Philippe Genne
CEO | Chief Executive Officer | 62 | 22-08-30 |
Karine Lignel
BRD | Director/Board Member | 55 | 22-09-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 1.3 | 0.00% | 4,918 |
| 24-05-16 | 1.3 | -1.52% | 11,907 |
| 24-05-15 | 1.32 | -2.22% | 21,163 |
| 24-05-14 | 1.35 | -2.17% | 20,542 |
| 24-05-13 | 1.38 | -2.13% | 837 |
Real-time Euronext Paris, May 17, 2024 at 11:35 am EDT
More quotes
Oncodesign Precision Medicine specializes in the research and development of therapeutic and diagnostic solutions in the clinical and preclinical areas of medical oncology. The company aims to discover new targeted therapy molecules for cancers without current solutions, including therapy-resistant and metastatic cancers.
Calendar
2024-06-25
- Shareholders Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.3
EUR
Average target price
2.48
EUR
Spread / Average Target
+90.77%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.18% | 23.54M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- ALOPM Stock
